Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2008

View Archived Issues

Paclitaxel-coated angioplasty balloons evaluated in leg angioplasty

Results of cardiac safety study of cethromycin reported

Spectrum receives Canadian approval to initiate phase III trials of EOquin for bladder cancer

Dosing begins in second phase III trial of CollaRx gentamicin for surgical site infections

USAMRIID study finds nanoviricides highly effective against Ebola virus

Recent Replidyne and Iqur patents disclose novel antiinfective agents

Novel therapeutic agents for dermatological disorders imparted in recent Maruzen patent

New therapeutic agents for viral hepatitis reported in recent Gilead patents

Phase II studies show promise of OGX-011 in prostate cancer

Data on UK-453061 in vitro activity, safety and potential for interactions reported

Phase I study finds picoplatin plus docetaxel safe in hormone-refractory prostate cancer

Mixed results seen with PI-88-docetaxel in hormone-refractory prostate cancer

Abiraterone active in phase I and II studies in castration-resistant prostate cancer

Encysive to be acquired by Pfizer

Additional orphan drug status granted to Marshall Edwards' triphendiol

Daiichi Sankyo and Lilly submit MAA to EMEA for prasugrel

Positive phase II data reported for ALN-RSV01 in RSV infection

Quest Diagnostics to develop blood test to aid in the detection of colorectal cancer

Cleveland Clinic initiates validation trial of SQI Diagnostics' SQiDworks platform

Biolex and Merck KGaA enter agreement to evaluate LEX System for antibody optimization

Northwest Biotherapeutics reports data from phase I/II clinical trials of DCVax-Brain

Sucampo Pharmaceuticals expands European presence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...